| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 3 data readout example | Ixo-vec (ixoberogene soroparvovec) Wet age-related macular degeneration (wet AMD) | Phase 3 | — | Gene Therapies | Ophthalmologic System | ||
phase 3 data readout example | Ixo-vec (ixoberogene soroparvovec) Wet age-related macular degeneration (wet AMD) | Phase 3 | — | Gene Therapies | Ophthalmologic System | ||
phase 3 data readout example | Ixo-vec (ixoberogene soroparvovec) Wet age-related macular degeneration (wet AMD) | Phase 3 | — | Gene Therapies | Ophthalmologic System |
Recent Updates
Recently added Catalysts
Adverum Biotechnologies, Inc.$4.36
+0.12 (+2.83%)
D 39Pipeline Score Fair Value Biotech · Clinical
Market Cap
96.26 M
EPS
-8.57
P/E Ratio
-
Value Trade
4.43 M
6.08 %
Week
2.11 %
1 Month
24.22 %
3 Month
54.61 %
6 Month
-96.81 %
5 Year
-98.26 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
1.02 M
52 Week Range
1.78 - 6.07
% held by Insiders
33.78 %
% held by Institutions
58.54 %
Enterprise Value
159.14 M
Total Shares
20.98 M
Short %
2.5 %
Float Shares
17.46 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D39
Pipeline Score $86M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored0.9x
rNPV / MCap Top 55%
Micro Cap (rank 408 of 905)
Percentile RankAdverum Biotechnologies, Inc. faces pipeline headwinds (39/100), with $1.8B risk-adjusted pipeline value, led by rAAV.sFlt-1 in Macular Degeneration (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rAAV.sFlt-1 Monoclonal antibody | Macular Degeneration | Phase 1 | NCT01494805 | 38% | $850M | COMPLETED | 40 | - | - | Aug 1, 2017 | - | Sep 1, 2017 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ADVM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ADVM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ADVM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ADVM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ADVM Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ADVM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How ADVM ranks across every disease it competes inCompetitive Position is a premium feature
See how ADVM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial